Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Noxxon Pharma AG - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Noxxon Pharma AG - Product Pipeline Review - 2016', provides an overview of the Noxxon Pharma AG's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Noxxon Pharma AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Noxxon Pharma AG - The report provides overview of Noxxon Pharma AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Noxxon Pharma AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Noxxon Pharma AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Noxxon Pharma AG's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Noxxon Pharma AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Noxxon Pharma AG's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Noxxon Pharma AG Snapshot 5 Noxxon Pharma AG Overview 5 Key Facts 5 Noxxon Pharma AG - Research and Development Overview 6 Key Therapeutic Areas 6 Noxxon Pharma AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Noxxon Pharma AG - Pipeline Products Glance 11 Noxxon Pharma AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Noxxon Pharma AG - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Noxxon Pharma AG - Drug Profiles 14 emapticap pegol - Drug Profile 14 Product Description 14 Mechanism Of Action 14 R&D Progress 14 lexaptepid pegol - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 NOXD-19 - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 NOXD-20 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 NOXD-21 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 NOXG-15 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 NOXG-16 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 NOXL-41 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 NOXS-93 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 olaptesed pegol - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Noxxon Pharma AG - Pipeline Analysis 29 Noxxon Pharma AG - Pipeline Products by Target 29 Noxxon Pharma AG - Pipeline Products by Route of Administration 30 Noxxon Pharma AG - Pipeline Products by Molecule Type 31 Noxxon Pharma AG - Pipeline Products by Mechanism of Action 32 Noxxon Pharma AG - Dormant Projects 33 Noxxon Pharma AG - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 35 Disclaimer 36
List of Tables Noxxon Pharma AG, Key Facts 5 Noxxon Pharma AG - Pipeline by Indication, 2016 8 Noxxon Pharma AG - Pipeline by Stage of Development, 2016 9 Noxxon Pharma AG - Monotherapy Products in Pipeline, 2016 10 Noxxon Pharma AG - Phase II, 2016 11 Noxxon Pharma AG - Phase I, 2016 12 Noxxon Pharma AG - Preclinical, 2016 13 Noxxon Pharma AG - Pipeline by Target, 2016 29 Noxxon Pharma AG - Pipeline by Route of Administration, 2016 30 Noxxon Pharma AG - Pipeline by Molecule Type, 2016 31 Noxxon Pharma AG - Pipeline Products by Mechanism of Action, 2016 32 Noxxon Pharma AG - Dormant Developmental Projects,2016 33 Noxxon Pharma AG, Subsidiaries 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.